SSP Group plc ( ($GB:SSPG) ) has provided an update. SSP Group plc has continued to execute its £100 million share repurchase programme, buying ...

Vernalis plc today announces its decision to cease further investment in V3381. An interim review of data from the small pilot study in chronic cough being undertaken in collaboration with Professor ...

OSB Group PLC ( ($GB:OSB) ) has provided an announcement. OSB Group PLC has repurchased 97,068 of its ordinary shares on 30 December 2025 across ...

RELX PLC (the “Company”) announces in compliance with the UK and EU Market Abuse Regulations that it will implement an irrevocable, non-discretionary programme to repurchase its ordinary shares ...

LONDON, UK / ACCESSWIRE / November 1, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company targeting diseases with a high unmet ...

Vesuvius plc ("Vesuvius"), a global leader in molten metal flow engineering and technology, is pleased to announce the commencement today of a further share buyback programme of up to £50 million (the ...

On 10 June 2025 FirstGroup plc (the ‘Group’) announced an on-market share buyback programme to purchase up to £50m of ordinary shares (the ’Programme’), which commenced on 10 June 2025. The Group ...

LEEDS, England, July 25, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on its oncology programmes.

Announcement of Non-Discretionary Share Buyback Programme and Cancellation of Shares held in Treasury RELX PLC (the “Company”) announces in compliance with the UK and EU Market Abuse Regulations that ...

LONDON, UK / ACCESSWIRE / June 29, 2023 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent ...